



ASX Release

March 2016 Appendix 4C

Melbourne, Australia, 21 April 2016

Prescient Therapeutics Limited (“**Prescient**” or “**the Company**”) provides the following Appendix 4C in relation to the quarter ended 31 March 2016.

Cash at 31 March 2016

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$1.7 million. The Company continues to maintain modest operational expenditure.

The Company received its 2014/2015 Research and Development Incentive Grant and Overseas Finding Grant amounting to \$463,538 during January 2016.

Key activities during the quarter

During the quarter, the Company announced the appointment of Mr Steven Yatomi-Clarke’s as Chief Executive Director and Managing Director of the Company. As a non-executive director of Prescient Therapeutics since its commencement and with qualifications in Biochemistry and Molecular Biology and Commerce, Steven was the ideal choice for the position. Further details of Mr Yatomi-Clarke’s appointment were announced on 15 February 2016.

During January 2016, the Company carried out investor roadshows in the US meeting key institutions and investors and also presented at Biotech Showcase 2016 in San Francisco and NobleCon12 in Florida.

Much of the clinical work during the quarter has been focused on finalising the preparations for the upcoming PTX-200 Phase 1b trial in Acute Myeloid Leukemia. In addition, progress continues on the PTX-200 breast cancer trial, with the last patient (patient 17) has been being dosed in the escalation stage of its Akt inhibition Phase 1b breast cancer trial at the Montefiore Cancer Center of Albert Einstein University in New York (Albert Einstein University) under the guidance of Professor Joseph Sparano. The trial targets women with metastatic and locally advanced HER2 negative breast cancer. The H. Lee Moffitt Cancer Center will join Albert Einstein University in the Phase 1b expansion cohort and Phase II trial.

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or



persistent platinum resistant ovarian cancer at Florida's H. Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX has recently received IND allowance for a Phase 1b/2 trial evaluating PTX-200 as a new therapy for Acute Myeloid Leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further Inquiries:

Steven Engle

Chairman

+1 858 922 7768 (US)

Paul Hopper

Executive Director

+61 406 671 515

Rudi Michelson

Monsoon Communications

+61 3 9620 3333

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/2010

Name of entity

Prescient Therapeutics Limited

ABN

56 006 569 106

Quarter ended ("current quarter")

31 March 2016

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (9 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) staff costs	(225)	(510)
(b) advertising and marketing	(11)	(35)
(c) research and development	(181)	(473)
(d) leased assets	-	-
(e) other working capital	(309)	(842)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	4	7
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other items		
(a) Net GST (paid to)/recovered from ATO	-	113
(b) R & D tax rebate received	465	559
(c) Government grant received	-	-
(d) R&D contract contributions received	-	-
Net operating cash flows	(257)	(1,181)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (9 months) \$A'000
1.8 Net operating cash flows (carried forward)	(257)	(1,181)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:	-	-
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	-	-
1.14 Total operating and investing cash flows	(257)	(1,181)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	1,971
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Capital raising costs	-	(202)
Net financing cash flows	-	1,769
Net increase (decrease) in cash held	(257)	587
1.21 Cash at beginning of quarter/year to date	1,930	1,043
Exchange rate adjustments to item 1.20	7	50
1.23 Cash at end of quarter	1,680	1,680

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	227
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Directors' fees and Executive Directors' salaries paid during the March 2016 quarter. The amount in 1.24 also includes amounts paid to the Company's previous Managing Director relating to outstanding employee entitlements.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

-

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	1,660	1,910
4.2	Deposits at call	20	20
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		1,680	1,930

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	-
5.2	Place of incorporation or registration	-
5.3	Consideration for acquisition or disposal	-
5.4	Total net assets	-
5.5	Nature of business	-

+ See chapter 19 for defined terms.

